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 Introduction 
 Obesity and its associated diseases have increased dra-
matically over the last decade  [1] . Surgical procedures 
such as Roux-en-Y gastric bypass (RYGB) do not merely 
reduce body weight but also ameliorate concomitant met-
abolic burden. Therefore, the term ‘metabolic surgery’ 
has gradually replaced ‘bariatric surgery’. Metabolic sur-
gery will soon be part of routine management algorithms 
for type 2 diabetes mellitus (T2DM) alongside and in con-
junction with lifestyle interventions and pharmacothera-
py  [2] .
 The numbers of metabolic surgery procedures world-
wide have risen steeply over the last years  [3] . Despite the 
fact that perioperative risks are increased and physiologi-
cal and anatomical conditions are altered in morbidly 
obese patients, there are few specific guidelines for the 
preoperative assessment of patients undergoing metabol-
ic surgery. Those that do exist are either not up to date or 
lack practical applicability further limiting their clinical 
use. Even though the perceived risk profile of obese pa-
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tients encourages clinicians to undertake thorough pre-
operative assessments, some of the diagnostic tools used 
should be questioned because they lack evidence that 
their use makes any difference. This review aims to pro-
vide a critical overview of preoperative assessment in 
obese patients planned for metabolic surgery.
 Multidisciplinary Care 
 Depending on the type of surgical procedure chosen, 
there is a variety of effects such as reduced hunger, in-
creased and prolonged satiation  [4, 5] , altered meal size 
frequency  [6] and food preferences  [7, 8] , micronutrient 
deficiencies  [9] , which all come along with manifold be-
havioral changes and adaptations from the patients. Fur-
thermore, functional problems including nausea, vomit-
ing, dehydration and benign abdominal pain account for 
about 50% of readmissions to the emergency department 
of the hospital within the first 3 months after metabolic 
surgery  [10] . Thus, most authors agree that a multidisci-
plinary team approach during the pre-, peri- and postop-
erative periods optimizes metabolic surgery patient care 
 [11] . Such a multidisciplinary team should include at least 
a bariatric surgeon, an internist with a focus on obesity 
medicine, a psychiatrist or psychologist as well as a nutri-
tionist and a clinical nurse specialist. Ideally, patients 
should be introduced to the entire team before surgery. 
 Although this interdisciplinary approach is generally ac-
cepted and regarded as common sense, there is in fact little 
scientific evidence that a multidisciplinary workup in the 
preoperative setting results in better outcome and reduced 
number of pre- and postoperative complications  [12] .
 Nutritional Assessment 
 Many morbidly obese patients have micronutrient de-
ficiencies  [13] , which can be exacerbated by the reduc-
tions in food intake and rearrangements of the gastroin-
testinal tract following metabolic surgery. Deficiencies in 
vitamins B 12 , B 1 , C, folate, A, D, and K and in iron, sele-
nium, zinc and copper are thought to be especially likely. 
Thus, regular monitoring of serum micronutrient levels 
should start preoperatively  [9] . Depending on the proce-
dure, most patients are prescribed daily multivitamin and 
trace mineral supplements after their surgery. General 
preoperative screening and unfocussed substitution of 
micronutrients again seems to be based more on com-
mon sense than evidence.
 Cardiovascular Assessment 
 Hypertension, hypercholesterolemia and T2DM are 
all classical risk factors for cardiovascular disease (CVD) 
and are significantly increased in obese individuals  [14] . 
Increased blood volume in these patients additionally may 
lead to left ventricular hypertrophy. Furthermore, obesity 
itself has been shown to be an independent risk factor for 
CVD particularly among women  [15] . Morbidly obese 
patients may thus be predisposed for cardiac events.
 Guidelines such as those of the American College of 
Cardiology and American Heart Association  [16] now use 
the revised cardiac risk index which includes history of 
ischemic heart disease, history of heart failure, and history 
of cerebrovascular disease, T2DM and renal insufficiency. 
The guidelines suggest that unstable coronary syndrome, 
decompensated heart failure, significant arrhythmias and 
severe valvular disease are contraindications for metabolic 
surgery because intraperitoneal surgery is classified as in-
termediate risk for coronary events. Even if metabolic sur-
gery is elective, the increased risk for myocardial infarction 
in the above-defined patient group may be 1–5% with po-
tentially fatal outcome and thus, metabolic surgery may not 
be justified in this group without better quality evidence.
 The increased cardiovascular risk has to be balanced 
with the expected benefits of metabolic surgery. For ex-
ample, a reduction of cardiovascular morbidity by ap-
proximately 25–50% has been demonstrated after meta-
bolic surgery when compared with BMI- and age-matched 
controls or those with nonsurgical weight loss  [17, 18] .
 A resting 12-lead electrocardiogram is performed rou-
tinely in most institutions, although there is no evidence 
of benefit as a screening tool for significant arrhythmias 
in patients without symptoms or clinical abnormalities in 
morbidly obese patients. In patients with at least 2 risk 
factors of ischemic heart disease and poor functional ca-
pacity, a noninvasive stress test by either a radionuclide 
myocardial perfusion imaging or a dobutamine stress 
echocardiography is recommended. Nevertheless, the 
considerable subcutaneous adipose tissue may make the 
interpretation of these tests very difficult and the risk of 
false-positives high. Functional capacity may be a better 
measurement. Adequate functional capacity can be de-
fined as 4 metabolic equivalents, which correspond to the 
climbing of 2 flights of stairs  [16] .
 Transthoracic dobutamine stress echocardiography 
may help stratify the cardiac dysfunction of morbidly 
obese patients and is safe. However, the low yield of pos-
itive tests together with a low positive predictive value for 
significant coronary artery disease questions its clinical 
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value  [19] . Thus, more invasive diagnostic tools like 
transesophageal stress echocardiography might be of 
greater value in some cases.
 The findings of echocardiography (e.g. eccentric car-
diac hypertrophy) and invasive tests can lead to a change 
of medical treatment or cardiological interventions like 
percutaneous thromboangioplasty or stenting. Numer-
ous studies have shown the benefit of starting medica-
tions, such as statins and β-blockers, in the preoperative 
setting to reduce cardiac risk  [20] . However, β-blockers 
to reduce the incidence of postoperative myocardial isch-
emia, myocardial infarction, and cardiac mortality by de-
creasing myocardial oxygen consumption and workload 
have not been studied specifically in morbidly obese pa-
tients  [19, 21] .
 If coronary stenting is needed, planned metabolic sur-
gery has to be postponed for approximately 1 year  [20] .
 Thromboembolic Risk Assessment 
 Flum et al. [22] showed in a prospective, observational 
study of 4,610 patients that venous thromboembolism is 
not only a complication of metabolic surgery but also a 
reliable predictor of adverse postoperative outcomes.
 Obesity contributes to the thromboembolic risk of 
surgery, which ranges from 0.15 to 2%  [22–24] . The low 
mortality of about 0.3% after metabolic surgery makes it 
difficult to identify the cause of death. However, in all ob-
servational studies investigating mortality related to met-
abolic surgery, pulmonary embolism (PE) is the most fre-
quent cause  [25] .
 Routine screening for phlebothrombosis by duplex so-
nography is not mandatory in the obese but recommend-
ed in patients with pulmonary hypertension or anteced-
ent deep vein thrombosis  [26] .
 Low-molecular-weight heparin (LMWH) in combina-
tion with sequential compression devices and early mo-
bilization are effective in reducing the risk of thrombo-
embolic events. Weight-based dose adjustments and ex-
tended prophylaxis may be beneficial  [27] .
 Due to the increased risk for thromboembolic compli-
cations in obese patients, some authors recommend the 
application of LMWH twice a day for patients with BMI 
>50, age >50 years, male sex, venous insufficiency, hy-
poventilation syndrome, smoking or history of thrombo-
sis  [23] . However, there is not yet enough evidence to sup-
port such aggressive prophylaxis regimens. 
 Other authors recommend that prophylactic place-
ment of a removable inferior vena cava filter should be 
considered for high-risk super-obese patients with BMI 
>55, a previous history of deep vein thrombosis, PE, or 
pulmonary hypertension (pulmonary artery pressure >40 
mm Hg). Gargiulo et al. [28] demonstrated in such a se-
lected patient group a reduction in PE with vena cava fil-
ter placement prior to open RYGB surgery. The reduced 
PE rates after laparoscopic surgery and the potentially se-
vere complications of vena cava filters may explain why 
this has not become a standard procedure.
 Pulmonary Assessment 
 Obesity impairs respiratory function by decreasing 
compliance of the lung and by increasing airway resis-
tance. Preoperative pulmonary spirometry might be use-
ful as a relatively simple screening tool because first, air-
flow obstruction and airflow reversibility probably in-
crease complications  [29] , and second, patients with 
impaired lung function may not have overt respiratory 
symptoms  [30] . 
 Obstructive sleep apnea syndrome (OSAS) and obe-
sity hypoventilation syndrome (OHS) may adversely af-
fect surgical outcome  [22] . OSAS is present in more than 
70% of the population undergoing metabolic surgery and 
remains undetected in more than 80% prior to surgery 
 [31] . OSAS and OHS can be diagnosed by polysomnog-
raphy and arterial blood gas analysis. OSAS with signifi-
cant hypoxia requires continuous positive airway pres-
sure (CPAP) therapy prior to surgery.
 The value of routine preoperative chest X-rays has long 
been disputed  [32] . In the absence of known cardiac or 
pulmonary disease, a chest X-ray changes the manage-
ment of patients only in 0.1%, suggesting that chest X-rays 
should be limited to patients with clinical findings  [33] .
 Metabolic Assessment 
 Obesity is an important risk factor for T2DM, and ap-
proximately 15–25% of morbidly obese patients have 
T2DM. Poor control of hyperglycemia in the first 24 h 
after surgery is associated with increased rates of postop-
erative infectious complications  [34] .
 Endocrine causes of obesity include hypothyroidism 
and Cushing’s disease. Although preoperative testing for 
such endocrine diseases very rarely yields results, some 
centers routinely use thyroid function testing, dexametha-
sone suppression tests and other endocrine diagnostics. 
Many centers refer all their patients for endocrinological 
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evaluation prior to surgery, even though there is only level 
D evidence as to the benefit of such preoperative workup 
 [12] . 
 Gastrointestinal Assessment 
 The role of preoperative upper endoscopy (EGD) in 
obese patients prior to metabolic surgery is controversial. 
Those that propagate a preoperative endoscopic assess-
ment of all patients point out its high diagnostic yield and 
the low cost. Sharaf et al. [35] reported that preoperative 
EGD revealed clinically important findings that affected 
the timing or choice of surgical treatment in 61.5% of 
their patients. In contrast, Schirmer et al. [36] reported 
that EGD changed the subsequent surgical treatment in 
only 5% of their cases.
 The high prevalence of  Helicobacter pylori (HP) alone 
does not justify preoperative EGD. First, because the prev-
alence of a pathological condition does not automatically 
implicate a treatment, and second, because a higher BMI 
is not associated with an increased risk for HP infection 
 [37] . However, the significantly lower incidence of mar-
ginal ulcers at the gastrojejunal anastomosis in patients 
who underwent preoperative EGD prior to RYGB surgery 
(p < 0.05) supports HP infection testing routinely in the 
preoperative assessment  [36] . Less invasive testing like 
13C urea breath test can be considered as an alternative. 
Screening for HP infection makes sense only if positive 
findings are followed by antibiotic therapy whose efficacy 
needs to be controlled before surgery, either by repeating 
EGD or by performance of a 13C urea breath test. 
 Obesity has been associated in several studies with a 
1- to 2-fold increase in the risk of gastroesophageal reflux 
disease (GERD) and its complications, such as erosive 
esophagitis and esophageal adenocarcinoma  [38] . Patter-
son et al. [39] have suggested that laparoscopic RYGB is 
not inferior to a Nissen fundoplication in improving 
GERD. Consequently, diagnosis of GERD should not al-
ter the use of RYGB surgery. In contrast, patients with 
GERD may not do as well with a sleeve gastrectomy as it 
can either lead to aggravation of GERD or even induce 
new onset of GERD in asymptomatic patients  [40] .
 Pancreatic Assessment 
 The follow-up data from the Swedish Obese Subject 
Study demonstrated that 2- and 10-year rates of recovery 
from diabetes were higher in the surgical group than in 
the control group, but that relapse remained a problem 
 [41] . More recent randomized controlled clinical trials 
indicate that metabolic surgery controls glycemia more 
effectively than medical care  [42, 43] . Nevertheless, very 
few published algorithms for the management of glyce-
mia immediately before and after surgery exist  [44] . 
 A recent Position Statement of the International Dia-
betes Federation recommends the use of diabetes-specific 
parameters to monitor the efficacy of treatment when 
metabolic surgery is performed in patients with T2DM 
 [45] . These recommendations include assessment of gly-
cated hemoglobin levels, C-peptide, fasting glycemia, in-
sulin levels, lipid profile, and regular monitoring of arte-
rial blood pressure, among others  [45] . 
 Hepatic Assessment 
 Nonalcoholic liver disease (NAFLD) is progressive in 
nature with 20–40% of nonalcoholic steatohepatitis cases 
turning into liver cirrhosis  [46] . NAFLD is predicted to 
be the primary cause for liver transplantation within the 
next decade  [47, 48] . Mosko and Nguen [49] investigated 
the bariatric surgical outcomes in patients with and with-
out liver cirrhosis. When compared to patients without 
liver cirrhosis, the odds ratio for in-hospital mortality was 
2.2 for patients with compensated cirrhosis, while pa-
tients with ascites and/or history of variceal bleeding had 
an odds ratio of 21.1. Patients whose clinical examination, 
medical history or clinical chemistry is suggestive of he-
patic disease should therefore undergo a thorough assess-
ment to quantify the severity of liver disease and presence 
of cirrhosis or portal hypertension. This in any case re-
quires imaging of the liver, often first by ultrasonography 
which also allows detection of splenomegaly and pres-
ence of ascites. If liver cirrhosis is suspected, a fibroscan 
or more invasive diagnostic tests such as liver biopsy and 
portal vein pressure measurements can be considered as 
further investigations.
 Some clinicians screen for the presence of cholecysto-
lithiasis which is increased in patients with a BMI >40. 
However, the indication for a routine concomitant cho-
lecystectomy in patients undergoing bariatric surgery re-
mains controversial. The reported incidence of new-on-
set symptomatic gallstone disease 3 years after RYGB in 
studies advocating prophylactic cholecystectomies rang-
es between 16  [50] and 19%  [51] .
 Plecka Ostlund et al. [52] explained the higher rate of 
gallbladder disease and need for cholecystectomy by a de-
tection bias in patients undergoing bariatric surgery.
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 In other studies, symptomatic gallstone disease occurs 
only in 6.9% of patients after RYGB surgery  [53] . Because 
multivariate analysis identified weight loss at 3 months 
after RYGB surgery of more than 50% of excess weight as 
the sole significant independent predictor of delayed 
symptomatic cholecystolithiasis, these authors conclud-
ed that prophylactic cholecystectomy should not be rec-
ommended at the time of RYGB  [53] .
 The added risk of a simultaneous cholecystectomy has 
to be balanced against its expected benefits. For example, 
there is no doubt that a cholecystectomy is technically less 
demanding and safer once the patient has lost a signifi-
cant amount of weight. On the other hand, an altered 
anatomy after procedures like an RYGB does not allow 
routine endoscopic investigations anymore and limits 
potential treatment options such as stent placing in the 
common bile duct in cases of bile duct injuries after cho-
lecystectomy.
 Renal Assessment 
 Obesity-associated comorbidities like T2DM and hy-
pertension increase not only the risk for cardiac events 
but also for chronic renal disease which is often over-
looked in patients undergoing weight loss surgery  [12] . In 
addition, obesity itself is an independent risk factor for 
the development and progression of chronic kidney dis-
ease  [54] . The predominant histological finding in renal 
biopsies of obesity-related renal disease is glomerulopa-
thy, alone or in combination with segmental glomerular 
sclerosis. Among the potential underlying pathophysio-
logical mechanisms, activation of the renin-angiotensin-
aldosterone system seems to be a key player  [55] . There-
fore, preoperative assessment for metabolic surgery 
should provide at least a screening for chronic renal dis-
ease.
 At present, renal transplant is the only curative treat-
ment for end-stage renal disease. As T2DM and obesity 
are important causes of graft failure and posttransplant 
complications, metabolic surgery in patients prior to or 
after renal or combined pancreas-kidney transplantation 
could become an important topic in the future. There are 
case reports of metabolic surgery after renal transplanta-
tions  [56, 57] , as well as case reports of bariatric surgery 
as a bridge for kidney transplantation in obese patients 
 [58] . The available literature consists of case reports and 
small case series allowing only vague and general assump-
tions: both sleeve gastrectomy and RYGB seem to be fea-
sible in patients prior to or after organ transplantation. 
RYGB surgery may, however, lead to significant changes 
in the pharmacokinetics of the most common immuno-
suppressive drugs such as tacrolimus, sirolimus and my-
cophenolate mofetil  [59] . If this justifies the intuitional 
preference for sleeve gastrectomy in these patients needs 
to be further studied.
 Psychological Assessment 
 Ideally, preoperative psychological assessment should 
rule out contraindications and establish patient’s readi-
ness for the behavioral challenges following metabolic 
surgery, in particular the capacity for postoperative com-
pliance. Almost all published studies and textbooks point 
out psychiatric contraindications for bariatric surgery. 
According to Bauchowitz et al. [60] , contraindications for 
metabolic surgery have included: substance abuse, severe 
mental retardation, multiple and recent suicide attempts, 
and active symptoms of psychosis, bipolar disorder, de-
pression or obsessive compulsive disorder. However, of-
ten statements related to psychiatric contraindications 
remain vague and are based on the assumption that the 
presence of any psychiatric conditions potentially im-
pairs the patients’ ability to cope with surgery  [61] . In a 
survey from 2006, which was referred to mental health 
professionals involved in the preoperative evaluation of 
obese patients, 92% listed psychiatric problems as ‘clear 
contraindications’ for surgery, but no single disorder or 
diagnostic category was listed as an important area of as-
sessment or as a contraindication by more than 45% of 
respondents  [62] . Part of the poor agreement was due to 
the wide variety of assessment methods used. Ashton et 
al. [63] stated that differences in testing instruments and 
varying definitions of psychopathological function and 
psychiatric diagnoses are a major problem in psychologi-
cal assessment. These authors in fact concluded that cur-
rently available methods lack predictive validity for meta-
bolic surgery outcome, and therefore it is not justified to 
use psychological assessment as an acceptance criterion 
for surgery. Others find this view too extreme and point 
out that some test modalities, such as a recent artificial 
neural network statistical model that incorporates both 
physical and psychological data, can indeed predict 
weight loss outcome with acceptable accuracy  [64] . Fur-
thermore, predicting surgical outcome is not the only rea-
son for multidisciplinary education of patients undergo-
ing metabolic surgery. For example, in one study preop-
erative education related to eating habits, psychological 
implications of surgery, its risks and disadvantages of bar-
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iatric surgery led 9% of patients to reject a surgery entire-
ly and another 15% to change the type of surgery chosen 
 [65] .
 However, there is no doubt that it is difficult to con-
vincingly demonstrate the preoperative need for a psy-
chosocial assessment compared to any other investiga-
tion during the preoperative assessment of patients 
planned to undergo metabolic surgery. 
 Holistic Scoring System 
 The King’s Staging Score is a proposed holistic method 
to better assess the risks for perioperative complications 
and patient coping strategies  [66] . It includes both so-
matic parameters and social criteria such as self-estima-
tion, and economic and functional status of the patient 
( table 1 ). Further validation and adaptation of such scores 
may help to better predict surgical outcome and the bur-
den a patient has to bear. However, the more detailed 
such an assessment is, the more (invasive) personal pre-
operative investigation is required.
 Conclusions 
 The many comorbidities and complications of morbid 
obesity are various and include all organ systems. While 
screening for cardiac diseases and chronic renal disease 
follows the general preoperative algorithm, metabolic, 
gastrointestinal and pulmonary assessment has to focus 
on specific aspects of obesity. The two major criteria for 
an adverse outcome of bariatric surgery are history of ve-
nous thromboembolism and/or OSAS. These conditions 
should not be missed, and the presence of OSAS may ne-
cessitate CPAP preoperatively. The preoperative gastro-
intestinal assessment should enable the diagnosis of HP-
positive gastritis which is common and increases the rate 
of marginal ulcers postoperatively. EGD is affordable and 
has a high diagnostic yield, but it is not essential. Psycho-
logical assessment at present lacks standardization, and 
most methods used have insufficient evidence for predic-
tive validity to recommend their use.
 
Table 1.  Modified King’s criteria
System/stage 0 I II III
Airway normal snoring OSAS with CPAP cor pulmonale
BMI <30 30 – 35 35 – 50 >50 
Body image normal does not like looking in mirror avoids mirrors severe eating disorder
Cardiovascular risk <25% risk >25% heart disease heart failure
Daily function 3 flights of stairs 1 or 2 flights of stairs <1 flight of stairs or walking aids house bound
Economic normal suffered discrimination unemployed requires financial support
Gastroesophageal junction normal heartburn esophagitis Barrett’s mucosa
Glucose homeostasis normal impaired fasting glycemia T2DM uncontrolled T2DM
Gonadal normal irregular menses PCOS/impotence infertility
Health status normal low mood or QoL moderate depression or poor QoL severe depression
Kidney normal proteinuria GFR <60 ml/min GFR <30 ml/min
Liver normal pathological LFT/NAFLD NASH liver failure
 PCOS = Polycystic ovary syndrome; GFR = glomerular filtration rate; LFT = liver function test; NASH = nonalcoholic steatohepatitis.
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